Get started

Chongqing Precision Biotech Co., Ltd. (China)

Alternate names: Chongqing Precision Biotech, Chongqing Precision Biotech Co., Ltd., Chongqing Precision Biotechnology Co., Ltd., Precision Biotech
ROR: 020r3wt94
OpenAlex ID: I4405267284
Bispecific Antibodies: From Research to Clinical Application
2021 · Jiabing Ma, Yicheng Mo, et al. · Frontiers in Immunology · 330
PDF
Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives
2022 · Yicheng Mo, Jiabing Ma, et al. · Frontiers in Cellular and Infection Microbiology · 175
PDF
Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors
2023 · Xiuxiu Zhu, Jun Chen, et al. · Cancer Research · 114
Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells
2024 · Xue He, Bin Hu, et al. · Autoimmunity Reviews · 55
Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection
2022 · Wuling Li, Xiuxiu Zhu, et al. · Frontiers in Immunology · 50
PDF
CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia
2021 · Yongliang Liu, Guiqin Wang, et al. · Stem Cell Research & Therapy · 37
PDF
Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma
2023 · Chengcheng Zhang, Linling Wang, et al. · Frontiers in Immunology · 36
PDF
Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.
2024 · Hangyu Zhang, Zhi Yang, et al. · Journal of Clinical Oncology · 27
Differential Mutation Detection Capability Through Capture-Based Targeted Sequencing in Plasma Samples in Hepatocellular Carcinoma
2021 · Jian Gao, Lei Xi, et al. · Frontiers in Oncology · 27
PDF
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
2023 · Li Shiqi, Zhang Jiasi, et al. · Molecular Therapy — Oncolytics · 23
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
2026 · Yang Gao, Jie Li, et al. · Nature Cancer · 20
Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study
2023 · Siyuan Qian, Jun Chen, et al. · Cytotherapy · 20
PDF
Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects
2022 · Siyuan Qian, Pedro Villarejo-Campos, et al. · Frontiers in Immunology · 20
PDF
Construction of self-driving anti-αFR CAR-engineered NK cells based on IFN-γ and TNF-α synergistically induced high expression of CXCL10
2024 · Min He, Xiang Ao, et al. · Neoplasia · 19
Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.
2025 · Shuang Wei, Jiaqi Guo, et al. · Journal of Clinical Oncology · 7
Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia
2025 · Wei Mu, Anqi Zhang, et al. · Blood · 5
PDF
Chimeric Antigen Receptor T-cell therapy in pediatric refractory systemic lupus erythematosus
2025 · Xue He, Fei Liu, et al. · The Innovation Medicine · 5
PDF
A novel co-receptor with mutated TIGIT to enhance PSCA CAR-T therapy for bladder cancer.
2024 · Junjie Shen, Depeng Dai, et al. · Journal of Clinical Oncology · 5
PDF
Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia
2025 · Mengli Xu, Shiqi Li, et al. · Blood · 3
PDF
Mechanical Properties Measured by Atomic Force Microscopy Help Evaluate Different Constructions of Re-engineered Chimeric Antigen Receptor-T Models
2025 · Leqian Zhao, Xuejiao Chen, et al. · ACS Nano · 3
A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population
2024 · Ruidong Zhang, Yang Cao, et al. · Blood · 3
PDF
"Armed" CEA CAR-T with a SIRPγ-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer.
2023 · Yongchun Zhao, Xiuxiu Zhu, et al. · Journal of Clinical Oncology · 3
PDF
Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases.
2026 · Hangyu Zhang, Jie Li, et al. · Journal of Clinical Oncology · 2
PDF
A Novel Platform to Manufacture High-Efficient "Off-the-Shelf" CAR-NK Products from Peripheral Blood Mononuclear Cells (PBMC)
2022 · Yukang Huang, Yunfan Chen, et al. · Blood · 2
Autologous CD19-directed CAR T cells produced by novel PrimeCARmanufacture platform exhibit safety, efficacy, and long persistence profiles in relapsed/refractory B-lineage acute leukemia (r/r B-ALL).
2022 · Shiqi Li, Zhi Yang, et al. · Journal of Clinical Oncology · 2
Works count: 39
Citation count: 3,881
Year
Topic
Type